Acetyl-macrocalin B, anent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer
- 13 April 2018
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 19 (7) , 609-621
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, and novel effective drugs against NSCLC are urgently needed. Isodon species are rich in ent-kaurane diterpenoids that have been reported to have antitumor bioactivity. Acetyl-macrocalin B (A-macB) is a novel ent-kaurane diterpenoid isolated from Isodon silvatica, and its antitumor efficacy against NSCLC and the underlying mechanisms were scrutinized in depth. The viability of cells treated with A-macB was detected by CCK-8 and colony formation assays. Apoptosis and cell cycle distribution were analyzed by flow cytometry. The mechanisms were investigated by detecting ROS and performing western blotting and verification experiments with specific inhibitors. The in vivo effect of A-macB was explored in a nude mouse xenograft model. A-macB effectively inhibited H1299 and A549 cell viability, triggered apoptosis and delayed cells in the G2/M phase. A-macB induced cellular ROS production and then activated the p38 MAPK-mediated, caspase 9-dependent apoptotic pathway. Both the ROS scavenger NAC and the specific p38 inhibitor SB203580 inactivated the function of p38 induced by A-macB, thus preventing cells from apoptosis. A-macB activated the Chk1/2-Cdc25C-Cdc2/cyclin B1 axis to induce G2/M phase arrest. AZD7762 abrogated the function of Chk1/2, abolished the G2/M delay and enhanced the cytotoxicity of A-macB. Moreover, A-macB efficiently suppressed tumor growth in a mouse xenograft model without noticeable toxicity to normal tissues. Having both efficacy and relative safety, A-macB is a potential lead compound that is worthy of further exploration for development as an anticancer agent.Keywords
Funding Information
- the National Key Research Development Plan (2016YFC0905400)
- the National Key Basic Research Development Plan (2014CB542006)
- the International Science and the Technology Corporation and Exchange Project (2015DFA31090)
- the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001)
- the Research Special Fund for Public Welfare Industry of Health (201402003)
- The National Natural Science Foundation of China (81673329)
- the NSFC-Joint Foundation of Yunnan Province (Grant U1302223)
This publication has 51 references indexed in Scilit:
- Androgens Upregulate Cdc25C Protein by Inhibiting Its Proteasomal and Lysosomal Degradation PathwaysPLOS ONE, 2013
- Natural products: An evolving role in future drug discoveryEuropean Journal of Medicinal Chemistry, 2011
- Treatment with the Chk1 inhibitor G�6976 enhances cisplatin cytotoxicity in SCLC cellsInternational Journal of Oncology, 2011
- Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?Journal of Signal Transduction, 2011
- Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to MitosisDevelopmental Cell, 2010
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2Current Opinion in Cell Biology, 2009
- p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageCancer Cell, 2007
- Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude miceEuropean Journal of Cancer, 2004
- Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysisOncogene, 2004